The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.09 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.52 — no flag raisedOK
- Earnings quality 94/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as PFIZER INC reports it. History and quarterly detail are in the app.
- Excluding Comirnaty and Paxlovid$54.5B
- Product$51.7B
- Primary Care$26.8B
- Specialty Care$17.5B
- Oncology$16.8B
Leadership changes
From PFIZER INC's own filings, the day they're filed.
- Cecile Guegan · Chief Financial Officer · departureeff. 2026-08-16
- Dave Denton · Chief Financial Officer · departureeff. 2026-08-15
- Mortimer J. Buckley · Directors · appointmenteff. 2024-10-10
Latest filings
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-06-18
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-04-27
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about PFIZER INC, every answer cited🔒
- The Intelligence Brief — added when PFIZER INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.